由于第三季度的强业绩和现金流的改善,ICU医疗公司将2025年利预测提高到7.35美元/7.65美元/股,超过预期. ICU Medical raised 2025 earnings forecast to $7.35–$7.65/share, beating estimates, on strong Q3 results and improved cash flow.

ICU Medical将其2025年收入指南提高到每股7.35至7.65美元,大大高于6.37美元的共识,在报告2025年Q3调整后,EPS比预期高出2.03至41.6%,收入5.37亿美元,高于先前的估计数,尽管同比下降8.9%。 ICU Medical raised its 2025 earnings guidance to $7.35–$7.65 per share, well above the $6.37 consensus, after reporting Q3 2025 adjusted EPS of $2.03—41.6% above expectations—and revenue of $537 million, up from prior estimates despite an 8.9% year-on-year decline. 该公司还将全年调整的EBITDA指南增加到4亿美元的中点,反映出现金流动和成本控制有所改善,尽管业务利润下降。 The company also increased full-year adjusted EBITDA guidance to a midpoint of $400 million, reflecting improved cash flow and cost controls, though operating margins dipped. 股权因强劲的结果和内幕购买而增加,而分析师则维持“机动购买”的评级。 Shares rose on strong results and insider purchases, while analysts maintain a "Moderate Buy" rating.